Edwards Lifesciences Co. (NYSE:EW) Receives Average Rating of “Hold” from Analysts

Edwards Lifesciences Co. (NYSE:EW) has been given an average recommendation of “Hold” by the twenty-five brokerages that are covering the company, Marketbeat reports. Fourteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $75.67.

A number of analysts recently commented on EW shares. UBS Group decreased their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Evercore ISI decreased their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Robert W. Baird decreased their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday.

Insider Activity

In related news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock valued at $1,099,238 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Solidarity Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $1,034,000. JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the last quarter. SteelPeak Wealth LLC increased its holdings in shares of Edwards Lifesciences by 24.9% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,666 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 732 shares during the last quarter. Diversify Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 20.2% in the 3rd quarter. Diversify Wealth Management LLC now owns 18,726 shares of the medical research company’s stock valued at $1,322,000 after acquiring an additional 3,150 shares during the last quarter. Finally, Evermay Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 351.4% in the 3rd quarter. Evermay Wealth Management LLC now owns 3,372 shares of the medical research company’s stock valued at $223,000 after acquiring an additional 2,625 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 1.4 %

Edwards Lifesciences stock opened at $69.38 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market capitalization of $41.81 billion, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock’s fifty day moving average is $68.08 and its two-hundred day moving average is $78.65.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 earnings per share. Analysts predict that Edwards Lifesciences will post 2.71 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.